PROM1 and glioma: In solid tumor models, a combination therapy of lenalidomide with CD133-specific CAR T cells led to enhanced in vitro cytotoxicity against the CD133 overexpressing human glioma cell line U251 and to increased proliferation of CAR T cells [89].